KMT2A and leukemia: Using a genetic approach, we compared the inhibitory effects of disrupting the AF9-DOT1L interaction or DOT1L enzymatic activity in leukemia cells harboring the MLL-AF9 oncoprotein as well as in non-leukemic adult bone marrow.